Raben David 4
4 · Bicara Therapeutics Inc. · Filed Nov 25, 2025
Insider Transaction Report
Form 4
Raben David
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-11-24$18.45/sh−5,500$101,475→ 35,497 total - Exercise/Conversion
Common Stock
2025-11-25$3.79/sh+4,594$17,410→ 40,091 total - Sale
Common Stock
2025-11-25$18.84/sh−4,594$86,562→ 35,497 total - Exercise/Conversion
Common Stock
2025-11-25$3.79/sh+906$3,434→ 36,403 total - Sale
Common Stock
2025-11-25$18.84/sh−906$17,071→ 35,497 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−5,500→ 123,370 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (5,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−4,594→ 118,776 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (4,594 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−906→ 69,413 totalExercise: $3.79Exp: 2023-08-08→ Common Stock (906 underlying) - Exercise/Conversion
Common Stock
2025-11-24$3.79/sh+5,500$20,844→ 40,997 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.68 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F4]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.